+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Lung Cancer Diagnostics - Global Market Trajectory & Analytics

  • ID: 4876858
  • Report
  • February 2022
  • Region: Global
  • 605 Pages
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Dr Lal PathLabs
  • F. Hoffmann-La Roche AG
  • Illumina Inc.
  • Myriad Genetics Inc.
  • NanoString Technologies
  • PlexBio Co., Ltd.

Global Lung Cancer Diagnostics Market to Reach $3.7 Billion by 2027


Amid the COVID-19 crisis, the global market for Lung Cancer Diagnostics estimated at US$2.2 Billion in the year 2020, is projected to reach a revised size of US$3.7 Billion by 2027, growing at a CAGR of 7.6% over the analysis period 2020-2027. Imaging Tests, one of the segments analyzed in the report, is projected to record a 7.1% CAGR and reach US$1.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Sputum Cytology segment is readjusted to a revised 7.8% CAGR for the next 7-year period.



The U.S. Market is Estimated at $587.7 Million, While China is Forecast to Grow at 11% CAGR


The Lung Cancer Diagnostics market in the U.S. is estimated at US$587.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$815.4 Million by the year 2027 trailing a CAGR of 11% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.2% and 5.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.

Molecular Tests Segment to Record 9.1% CAGR


In the global Molecular Tests segment, USA, Canada, Japan, China and Europe will drive the 8.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$236.3 Million in the year 2020 will reach a projected size of US$421 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$503.5 Million by the year 2027, while Latin America will expand at a 10.3% CAGR through the analysis period.

Select Competitors (Total 48 Featured) -

  • Abbott Diagnostics - Core Laboratory
  • Dr Lal PathLabs
  • F. Hoffmann-La Roche AG
  • Illumina Inc.
  • Myriad Genetics Inc.
  • NanoString Technologies
  • NeoGenomics Laboratories Inc.
  • PlexBio Co., Ltd.
  • QIAGEN GmbH
  • Quest Diagnostics
  • Thermo Fisher Scientific Inc.
Frequently Asked Questions about the Global Market for Lung Cancer Diagnostics

What is the estimated value of the Global Market for Lung Cancer Diagnostics?

The Global Market for Lung Cancer Diagnostics was estimated to be valued at $2.2 Billion in 2020.

What is the growth rate of the Global Market for Lung Cancer Diagnostics?

The growth rate of the Global Market for Lung Cancer Diagnostics is 7.7%, with an estimated value of $3.7 Billion by 2027.

What is the forecasted size of the Global Market for Lung Cancer Diagnostics?

The Global Market for Lung Cancer Diagnostics is estimated to be worth $3.7 Billion by 2027.

Who are the key companies in the Global Market for Lung Cancer Diagnostics?

Key companies in the Global Market for Lung Cancer Diagnostics include Abbott Diagnostics, Core Laboratory, Dr Lal PathLabs, F. Hoffmann, La Roche AG, Illumina Inc., Myriad Genetics Inc., NanoString Technologies and PlexBio Co., Ltd..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Dr Lal PathLabs
  • F. Hoffmann-La Roche AG
  • Illumina Inc.
  • Myriad Genetics Inc.
  • NanoString Technologies
  • PlexBio Co., Ltd.

I. METHODOLOGY


II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Early Detection of Lung Cancer Takes Precedence, Driving the Demand for Lung Cancer Diagnostics
  • Non-small Cell Lung Cancer - The More Prominent of the Two Lung Cancer Types
  • Imaging Tests Segment Dominates the Market, Molecular Tests Category to Witness High Growth
  • US Leads the Lung Cancer Diagnostics Market, Asia-Pacific to Witness Fastest Growth
  • Lung Cancer Diagnostics – Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

  • Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Early Diagnoses
  • Age-Standardized Lung Cancer Rates for Select Countries
  • Age-Standardized Lung Cancer Rates in Men for Select Countries
  • Age Standardized Lung Cancer Rates in Women for Select Countries
  • Lung Cancer-Specific Biomarkers to Spur Market Growth
  • Select Lung Cancer Biomarkers
  • New Potential Biomarker for Early Stage Lung Cancer Identified in a Recent NCI Study (2019)
  • Advancements and Research Initiatives in Lung Cancer Diagnostics Space
  • EFIRM Test for Detection of Lung Cancer-related EGFR Mutations in NSCLC Patients
  • A Glance at Select Recent Launches of Lung Cancer Diagnostic Tests
  • New Product Launches/Approvals in the Lung Cancer Diagnostics
  • Recent Approvals
  • Liquid Biopsies Grow in Value as a Diagnostic Tool Supporting Therapy Decisions in NSCLCs
  • Effervescent Rate of New Innovations & Product Development Will Make Liquid Biopsy a Readily Available Option for Patients in the Coming Years
  • High Cigarette Consumption/Rise in Prevalence of Smoking Increases the Incidence of Lung Cancer
  • Cigarette Consumption Per Year Per Person Across Select Countries: 2016
  • Top 15 Countries with the Highest Smoking Rates: 2015
  • Increasing Number of Awareness Programs for Lung Cancer and Symptoms
  • Growing Availability of Government/Private Funding for R&D to Develop Lung Cancer Diagnostics
  • National Cancer Institute Research Funding for Lung Cancer in US$ Million for the Years 2014 through 2017
  • Aging Demographics & Unhealthy Lifestyles Raise the Risk of Cancer
  • Cancer Prone Sites based on Age
  • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050

4. GLOBAL MARKET PERSPECTIVE


III. MARKET ANALYSIS

UNITED STATES

  • Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
  • Lung Cancer Stats
  • US Lung and Bronchus Cancer New Cases by Gender: 2019E
  • US Lung and Bronchus Cancer Deaths by Gender: 2019E
  • Incidence Rates* for Lung and Bronchus Cancer by Gender, 2011-2015
  • Death Rates* for Lung and Bronchus Cancer by Gender in the US, 2012-2016
  • Incidence Rates for Lung and Bronchus Cancer by Race/Ethnicity, 2011-2015
  • Reimbursement and Insurance Coverage for Lung Cancer Screening in the US
  • CY 2019 Medicare Physician Fee Payment Levels for Low Dose CT Scan (LDCT) Screening
  • CY 2019 Hospital Outpatient Prospective Payment System (HOPPS) Payment Levels for Low Dose CT Scan (LDCT) Screening
  • Oncimmune’s EarlyCDT Lung to be commercialized in the US by Biodesix (2019)
  • Market Analytics

CANADA

JAPAN

  • Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)

CHINA

  • Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)

EUROPE

  • Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)

FRANCE

  • Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)

GERMANY

  • Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)

ITALY

UNITED KINGDOM

  • Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
  • UK Age-standardised Rate (per 100,00) of Lung Cancer Cases by Gender: 1980-2035P

SPAIN


RUSSIA


REST OF EUROPE

ASIA-PACIFIC

  • Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)

AUSTRALIA

  • Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)

INDIA

  • Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
  • Rise in Incidence of Lung Cancer in India
  • New Cancer Cases in India by Site: 2018

SOUTH KOREA


REST OF ASIA-PACIFIC

LATIN AMERICA

  • Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)

ARGENTINA


BRAZIL


MEXICO


REST OF LATIN AMERICA

MIDDLE EAST

  • Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)

IRAN


ISRAEL


SAUDI ARABIA


UNITED ARAB EMIRATES


REST OF MIDDLE EAST

AFRICA

  • Lung Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)

IV. COMPETITION

  • Total Companies Profiled: 48
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Diagnostics - Core Laboratory
  • Dr Lal PathLabs
  • F. Hoffmann-La Roche AG
  • Illumina Inc.
  • Myriad Genetics Inc.
  • NanoString Technologies
  • NeoGenomics Laboratories Inc.
  • PlexBio Co., Ltd.
  • QIAGEN GmbH
  • Quest Diagnostics
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown